This podcast was funded by and developed in collaboration with AstraZeneca.

Learning Objectives:

At the conclusion of this activity, participants will be able to:

1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy.

2. Evaluate available clinical safety and efficacy data for PARP Inhibitors.

3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer.

4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors.

For more information: https://auau.auanet.org/content/overview-parpi-adverse-event-management-podcast-2021